EJHaem · 2026
Mogamulizumab as Bridge to Thiotepa-Based Allogeneic Haematopoietic Stem Cell Transplantation in Sézary Syndrome: A Single-Centre Experience.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maifredi Simone, Sala Raffaella, Bottelli Chiara, Pagani Chiara, Passi Angela, Daffini Rosa, Pantaleo Alessia, Russo Domenico, Malagola Michele, Venturini Marina, Avenoso Daniele, Tucci Alessandra
Аннотация
INTRODUCTION: Sézary syndrome (SS) is an aggressive cutaneous T-cell lymphoma for which allogeneic haematopoietic stem cell transplantation (allo-HSCT) represents the only potentially curative treatment.
METHODS: We report a single-centre series of three consecutive SS patients treated with mogamulizumab as bridging therapy to allo-HSCT using thiotepa-based reduced-intensity conditioning.
RESULTS: Mogamulizumab induced rapid clearance of circulating Sézary cells and significant clinical improvement. All patients achieved early and stable full donor chimerism and complete remission. Post-transplant GVHD occurred but was manageable with standard therapy.
CONCLUSION: Early use of mogamulizumab may provide effective disease control and facilitate successful allo-HSCT in SS.
TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.
METHODS: We report a single-centre series of three consecutive SS patients treated with mogamulizumab as bridging therapy to allo-HSCT using thiotepa-based reduced-intensity conditioning.
RESULTS: Mogamulizumab induced rapid clearance of circulating Sézary cells and significant clinical improvement. All patients achieved early and stable full donor chimerism and complete remission. Post-transplant GVHD occurred but was manageable with standard therapy.
CONCLUSION: Early use of mogamulizumab may provide effective disease control and facilitate successful allo-HSCT in SS.
TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.